The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO‐QOL) after different treatments
Abstract
The Graves' ophthalmopathy quality of life questionnaire (GO‐QOL) is the first instrument available to measure health‐related quality of life (HRQL) of patients with Graves' ophthalmopathy. The main objective of this study was to define a minimal clinically important difference (MCID) in score on the GO‐QOL that can be considered an important improvement in HRQL by examining changes in GO‐QOL scores in patients who subjectively report improvement from their treatment. A secondary objective was to test the longitudinal validity of the GO‐QOL, using prespecified hypotheses about expected treatment effects. A prospective cohort study. We included 164 patients who were scheduled for radiotherapy (23), orbital decompression (10 for sight loss, 38 for exophthalmos), eye muscle surgery (31), eyelid lengthening (43) or blepharoplasty (19). Patients completed the GO‐QOL and three general HRQL questionnaires, before and three or six months after treatment, depending on the performed procedure. Clinical characteristics were collected from the medical records. Mean changes in GO‐QOL scores and effect sizes were calculated after different treatments, and in subgroups of responders and nonresponders according to clinical characteristics and according to the patients themselves. A clinical response to treatment was associated with a change in GO‐QOL scores of approximately 10–20 points after major treatments (radiotherapy or decompression), and with a change of approximately 3–10 points after minor surgery (eye muscle surgery, eyelid lengthening, blepharoplasty). Changes in GO‐QOL scores of about 6–10 points were considered important improvements by the patients themselves. The direction and amount of change in GO‐QOL scores after different treatments were in accordance with our prespecified hypotheses about treatment effects. Effect sizes in the GO‐QOL subscales were generally higher than effect sizes of the general HRQL subscales, supporting the longitudinal validity of the GO‐QOL. As a general guideline, one could consider a mean change of at least 6 points on one or both subscales an important change in daily functioning for patients. For more invasive therapies, a change of at least 10 points is recommended as a minimal clinically important difference.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401
Cited by
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Self-citationBartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Self-citationTeprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Douglas, R. S., Kahaly, G. J., Patel, A., Sile, S., Thompson, E. H. Z., Perdok, R., Fleming, J. C., Fowler, B. T., Marcocci, C., Marinò, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910434 · Cited by 752
Terwee, C. B., Dekker, F. W., Wiersinga, W. M., Prummel, M. F., & Bossuyt, P. M. M. (2003) · Quality of Life Research · doi:10.1023/a:1023499322593 · Cited by 664
Self-citation
Metadata
- Authors
- Terwee, C. B., Dekker, F. W., Mourits, M. P., Gerding, M. N., Baldeschi, L., Kalmann, R., Prummel, M. F., & Wiersinga, W. M.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2001-03
- Volume
- 54
- Issue
- 3
- Pages
- 391-398
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2136188216
- Cited by
- 202
- References
- 3
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO‐QOL) after different treatments. https://app.cochat.ai/papers/10.1046/j.1365-2265.2001.01241.x
- The paper
- Terwee, C. B., Dekker, F. W., Mourits, M. P., Gerding, M. N., Baldeschi, L., Kalmann, R., Prummel, M. F., & Wiersinga, W. M. (2001). Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO‐QOL) after different treatments. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2001.01241.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.